Published Online
on June 4, 2009

A more recent version of this article appeared on July 1, 2009

This Article Full Text (PDF) All Versions of this Article: 40/7/2295    most recent STROKEAHA.109.552398v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kurth, T. Articles by Tzourio, C. Search for Related Content PubMed PubMed Citation Articles by Kurth, T. Articles by Tzourio, C. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Stroke Related Collections Acute Cerebral Infarction Related Article

Treating Patients With Ischemic Stroke With Tissue Plasminogen Activator in the 3.5- to 4-Hour Window. Numbers Support Benefit but the Message Is to Still Go Fast

Tobias Kurth MD, ScD^* and Christophe Tzourio MD, PhD

From the INSERM Unit 708–Neuroepidemiology (T.K., C.T.) and Faculty of Medicine, University Pierre et Marie Curie, Paris, France; Division of Preventive Medicine (T.K.), Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass; Department of Epidemiology (T.K.), Harvard School of Public Health, Boston, Mass.

^* To whom correspondence should be addressed. E-mail: tobias.kurth{at}upmc.fr.

Key words: methodology • stroke care • tissue plasminogen activator

Related Article:

Number Needed to Treat to Benefit and to Harm for Intravenous Tissue Plasminogen Activator Therapy in the 3- to 4.5-Hour Window: Joint Outcome Table Analysis of the ECASS 3 Trial

Jeffrey L. Saver, Jeffrey Gornbein, James Grotta, David Liebeskind, Helmi Lutsep, Lee Schwamm, Phillip Scott, and Sidney Starkman
Stroke 2009 40: 2433-2437. [Abstract] [Full Text] [PDF]